Cart
sales@molnova.com
Ningetinib
CAS No. 1394820-69-9
Ningetinib( CT-053,CT053PTSA )
Catalog No. M22115 CAS No. 1394820-69-9
Ningetinib (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 71 | In Stock |
|
| 2MG | 40 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 92 | In Stock |
|
| 25MG | 188 | In Stock |
|
| 50MG | 319 | In Stock |
|
| 100MG | 546 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNingetinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionNingetinib (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
-
DescriptionNingetinib (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.In cell-based functional assays, Ningetinib inhibits VEGF and HGF-stimulated HUVEC proliferation and microvascular angiogenesis in rat aortic rings with IC50 values of 6.3 and 8.6 nM, respectively.In the orthotopic U87MG human glioblastoma xenograft model, Ningetinib prolongs the median survival time and yields a significant increase in life-span value (ILS=32%) at an oral dose of 20 mg/kg/day (dosed 21 days) versus the vehicle-treated group. When single dosed orally (3 mg/kg) to U87MG tumor-bearing nude mice, Ningetinib potently inhibits the phosphorylation of c-Met and its downstream signaling kinases AKT and ERK1/2 for up to 6 hours in tumor tissues.
-
In Vitro——
-
In Vivo——
-
SynonymsCT-053,CT053PTSA
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
Recptorc-Met| VEGFR2| AXL
-
Research AreaCancer
-
IndicationNon-small cell lung Cancer; Renal Cancer
Chemical Information
-
CAS Number1394820-69-9
-
Formula Weight556.58
-
Molecular FormulaC31H29FN4O5
-
Purity>98% (HPLC)
-
SolubilityDMSO:15 mg/mL (26.95 mM; Need ultrasonic)
-
SMILESCc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ning Xi, et al. Abstract 1755: CT053PTSA, a novel c-MET and VEGFR2 inhibitor, potently suppresses angiogenesis and tumor growth. Cancer Res 2014;74(19 Suppl):Abstract nr 1755.
molnova catalog
related products
-
TRX818
TRX-818 is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities.
-
Glumetinib
Glumetinib (SCC 244)?is a novel potent and highly selective inhibitor of c-Met kinase with IC50 of 0.42 nM.
-
Capmatinib hydrochlo...
Capmatinib hydrochloride is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Capmatinib was found to be highly selective for MET over other kinases.?It was active against cancer models that are characterized by MET amplification, marked MET overexpression, MET exon 14 skipping mutations, or MET activation via expression of the ligand hepatocyte growth factor (HGF).
